January 18, 2023
RegMed Investors’ (RMi) closing bell: momentum rolls downhill as economic data exchanges the scenario to a negative close
January 17, 2023
RegMed Investors’ (RMi) closing bell: share pricing slips on the icy surface as the sector dives
January 13, 2023
RegMed Investors’ (RMi) closing bell: cell/gene therapy sector wavers paring upside yet closes scarcely positive
January 12, 2023
RegMed Investors’ (RMi) closing bell: cell/gene therapy sector appreciated in recent sessions as CPI report confirmed a weakening inflation trend
January 11, 2023
RegMed Investors’ (RMi) closing bell: sector gains, follow Tuesday’s advances post Monday’s pain
January 10, 2023
RegMed Investors’ (RMi) closing bell: the sector experiences a tailwind with the merry-go-round still spinning tomorrow
January 9, 2023
RegMed Investors’ (RMi) closing bell: JPM23 rippled share pricing with most positive equities inching upward
January 6, 2023
RegMed Investors’ (RMi) closing bell: jobs economic data pushes market and cell/gene therapy sector uphill
January 5, 2023
RegMed Investors’ (RMi) closing bell: it’s the economy, stupid
January 4, 2023
RegMed Investors’ (RMi) closing bell: sector churns higher
January 3, 2023
RegMed Investors’ (RMi) closing bell: 2023 first session of pain as recessionary perceptions initiated sudden decline
December 30, 2022
RegMed Investors’ (RMi) closing bell: 2022 rushed into its session, week, month and year end with a positive close
December 29, 2022
RegMed Investors’ (RMi) closing bell: uncle algorithms to the upside
December 28, 2022
RegMed Investors’ (RMi) closing bell: sector expectation defined
December 27, 2022
RegMed Investors’ (RMi) closing bell: downside spirals as 2022 fades
December 23, 2022
RegMed Investors’ (RMi) closing bell: low liquidity and thin volume
December 22, 2022
RegMed Investors’ (RMi) closing bell: selling returned Thursday
December 21, 2022
RegMed Investors’ (RMi) closing bell: two-day confidence bounce
December 20, 2022
RegMed Investors’ (RMi) closing bell: thinking about getting back invested to the sector – DON’T and WAIT
December 19, 2022
RegMed Investors’ (RMi) closing bell: residual negativity haunts our universe of cell and gene therapy is severely damaged
December 16, 2022
RegMed Investors’ (RMi) closing bell: sector extends losses as selling pressure continues
December 15, 2022
RegMed Investors’ (RMi) closing bell: cell and gene therapy sector bottoms
December 14, 2022
RegMed Investors’ (RMi) closing bell: cell and gene therapy sector craters as Fed rate decision unfolds with more hikes next year
December 13, 2022
RegMed Investors’ (RMi) closing bell: indexes slow and some sector gains evaporate post CPI release
December 12, 2022
RegMed Investors’ (RMi) closing bell: cell and gene therapy sector opened and closed higher as oversold were “recognized” in-front of CPI and Fed meeting report
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2025 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.